Financial Snapshot

Revenue
$6.728M
TTM
Gross Margin
27.14%
TTM
Net Earnings
-$3.576M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
151.25%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$4.986M
Q3 2024
Cash
Q3 2024
P/E
-9.412
Nov 29, 2024 EST
Free Cash Flow
-$4.062M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $4.089M $2.048M $1.551M $674.0K $717.0K $2.213M
YoY Change 99.66% 32.04% 130.12% -6.0% -67.6%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $4.089M $2.048M $1.551M $674.0K $717.0K $2.213M
Cost Of Revenue $3.470M $1.792M $1.542M $965.0K $854.0K $1.699M
Gross Profit $619.0K $256.0K $9.000K -$291.0K -$137.0K $514.0K
Gross Profit Margin 15.14% 12.5% 0.58% -43.18% -19.11% 23.23%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $3.867M $3.237M $2.548M $1.969M $1.763M $2.373M
YoY Change 19.46% 27.04% 29.41% 11.68% -25.71%
% of Gross Profit 624.72% 1264.45% 28311.11% 461.67%
Research & Development $103.0K $367.0K $31.00K
YoY Change -71.93% 1083.87%
% of Gross Profit 16.64% 143.36% 344.44%
Depreciation & Amortization $226.0K $112.0K $113.0K $50.00K $67.00K $322.0K
YoY Change 101.79% -0.88% 126.0% -25.37% -79.19%
% of Gross Profit 36.51% 43.75% 1255.56% 62.65%
Operating Expenses $4.096M $3.604M $2.579M $1.969M $1.787M $2.402M
YoY Change 13.65% 39.74% 30.98% 10.18% -25.6%
Operating Profit -$3.477M -$3.348M -$2.570M -$2.260M -$1.924M -$1.888M
YoY Change 3.85% 30.27% 13.72% 17.46% 1.91%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $176.0K -$1.251M -$1.990M -$12.00K $1.000K $0.00
YoY Change -114.07% -37.14% 16483.33% -1300.0%
% of Operating Profit
Other Income/Expense, Net $113.0K -$1.398M -$1.740M -$4.000K $0.00 $0.00
YoY Change -108.08% -19.66% 43400.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$3.188M -$4.746M -$4.310M -$2.264M -$1.923M -$1.888M
YoY Change -32.83% 10.12% 90.37% 17.73% 1.85%
Income Tax $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.157M -$4.700M -$4.310M -$2.264M -$1.923M -$1.888M
YoY Change -32.83% 9.05% 90.37% 17.73% 1.85%
Net Earnings / Revenue -77.21% -229.49% -277.89% -335.91% -268.2% -85.31%
Basic Earnings Per Share -$0.56 -$0.85 -$1.45 -$1.05
Diluted Earnings Per Share -$0.56 -$0.85 -$1.45 -$1.05 -$345.5K -$339.3K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $2.700M $6.609M $13.35M $32.00K $261.0K $0.00
YoY Change -59.15% -50.49% 41618.75% -87.74%
Cash & Equivalents
Short-Term Investments $0.00 $5.508M
Other Short-Term Assets $400.0K $172.0K $77.00K $25.00K $37.00K $226.0K
YoY Change 132.56% 123.38% 208.0% -32.43% -83.63%
Inventory $1.319M $502.0K $291.0K $233.0K $113.0K $101.0K
Prepaid Expenses
Receivables $633.0K $222.0K $209.0K $73.00K $102.0K $34.00K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $5.052M $7.505M $13.93M $363.0K $513.0K $361.0K
YoY Change -32.68% -46.11% 3736.64% -29.24% 42.11%
Property, Plant & Equipment $3.354M $2.458M $2.649M $1.358M $1.199M $200.0K
YoY Change 36.45% -7.21% 95.07% 13.26% 499.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $95.00K $63.00K $63.00K $178.0K $178.0K $178.0K
YoY Change 50.79% 0.0% -64.61% 0.0% 0.0%
Total Long-Term Assets $4.903M $2.852M $3.056M $1.894M $1.377M $378.0K
YoY Change 71.91% -6.68% 61.35% 37.55% 264.29%
Total Assets $9.955M $10.36M $16.98M $2.257M $1.890M $739.0K
YoY Change
Accounts Payable $1.233M $265.0K $254.0K $658.0K $510.0K $157.0K
YoY Change 365.28% 4.33% -61.4% 29.02% 224.84%
Accrued Expenses $294.0K $337.0K $269.0K $297.0K $234.0K $250.0K
YoY Change -12.76% 25.28% -9.43% 26.92% -6.4%
Deferred Revenue
YoY Change
Short-Term Debt $245.0K $0.00 $2.037M $59.00K $0.00 $0.00
YoY Change -100.0% 3352.54%
Long-Term Debt Due $80.00K $15.00K $10.00K $157.0K $0.00
YoY Change 433.33% 50.0% -93.63%
Total Short-Term Liabilities $2.549M $859.0K $2.888M $1.332M $800.0K $407.0K
YoY Change 196.74% -70.26% 116.82% 66.5% 96.56%
Long-Term Debt $513.0K $268.0K $266.0K $256.0K $0.00 $0.00
YoY Change 91.42% 0.75% 3.91%
Other Long-Term Liabilities $1.727M $1.593M $1.744M $598.0K $710.0K $51.00K
YoY Change 8.41% -8.66% 191.64% -15.77% 1292.16%
Total Long-Term Liabilities $2.240M $1.861M $2.010M $854.0K $710.0K $51.00K
YoY Change 20.37% -7.41% 135.36% 20.28% 1292.16%
Total Liabilities $5.258M $2.720M $4.898M $2.186M $1.510M $458.0K
YoY Change 93.31% -44.47% 124.06% 44.77% 229.69%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 5.672M shares 5.575M shares 2.980M 2.254M 13.57M
Diluted Shares Outstanding 5.672M shares 5.575M shares 2.980M 2.254M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $33.659 Million

About NEXGEL, INC.

NexGel, Inc. engages in the manufacture of aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Langhorne, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-12-22. The company is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. The company also specializes in eye and eyelash consumer products.

Industry: Surgical & Medical Instruments & Apparatus Peers: SURGALIGN HOLDINGS, INC. Predictive Oncology Inc. CHEMBIO DIAGNOSTICS, INC. Rapid Therapeutic Science Laboratories, Inc. Innovative Eyewear Inc ROCKWELL MEDICAL, INC. Sharps Technology Inc.